Consensus Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Market Closed - BME Other stock markets 11:35:15 2024-05-13 am EDT			5-day change	1st Jan Change
1.952 ^EUR	+0.10%		-0.91%	+3.39%

May. 06	Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	CI

Evolution of the average Target Price on Oryzon Genomics S.A.

Price target over the last 5 years

History of analyst recommendation changes

3694a25163a5d54368.kQcahU6elymUo0USyUS2KcpLXl1Pxxbwb6spyTvV1L8.8kMj6iTt7xDx7yhDqAH8XIApGQIEkWa_G-hjqHnn7NbrYUDEJa7nUdPAHA~816a2985e261672d712e85c010fc297c

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.952 EUR

Average target price

6.694 EUR

Spread / Average Target

+242.95%

High Price Target

12 EUR

Spread / Highest target

+514.75%

Low Price Target

2.5 EUR

Spread / Lowest Target

+28.07%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar